Group 1 - Jiangxi Biological Products Research Institute Co., Ltd. (referred to as Jiangxi Biological) submitted its Hong Kong IPO prospectus on April 11, which became invalid after six months on October 11 [1] - CICC (601995) and China Merchants Securities International served as joint sponsors for the IPO [1] Group 2 - According to Frost & Sullivan, Jiangxi Biological is the largest provider of human TAT (tetanus antitoxin) in China and globally, with market shares of 65.8% and 36.6% respectively based on 2024 sales [1] - Tetanus antitoxin is a type of antiserum that provides immediate protection and treatment by neutralizing the toxins produced by Clostridium tetani, the bacteria that causes tetanus, thus preventing and treating tetanus infections [1]
江西生物港股IPO招股书失效
Zhi Tong Cai Jing·2025-10-13 01:04